Risk Stratification in MDS
Treating Patients With Lower-Risk MDS
- Managing anemia
- Treating isolated thrombocytopenia and pancytopenia
- LR MDS with del(5q)
- Novel targeted therapies for LR MDS
Managing Higher-Risk MDS
- Anti-CD47 agents
- Novel hypomethylating agents and combinations
- Other therapies
When to Treat MDS with AlloHSCT
AE Management and Patient Education
Question and Answer Session
Date / Time
Amy E. DeZern, MD, MHS
Oncology and Medicine
The Johns Hopkins University School of Medicine
Daniel A. Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Division of Hematology
University of Colorado School of Medicine
Amer Zeidan, MBBS
Associate Professor, Internal Medicine
New Haven, Connecticut
In this live 1-hour Webinar, 3 expert faculty discuss key areas of consensus and controversy involving the latest data, new indications, and emerging novel therapies for patients with MDS.
The goal of this activity is to educate hematologists, oncologists, nurses, pharmacists, and other practitioners in hematology/oncology about the recent developments in the care of MDS and incorporating new data and new therapies into their patient treatment plans.
This educational program is intended for hematologists, oncologists, nurses, pharmacists, and other practitioners in hematology/oncology who care for patients with MDS.
Upon completion of this activity, participants should be able to:
- Plan therapeutic strategies for patients with MDS based on diagnostic classification, patient age and fitness, and risk stratification
- Integrate the available clinical data, treatment guidelines, and expert recommendations when selecting treatment in the settings of low-, intermediate-, and high-risk groups, as well as MDS with adverse or targetable genetic features
- Recognize and manage adverse events associated with current and recently approved systemic therapies in MDS
- Evaluate the available clinical data on promising investigational agents and emerging combination therapies for managing high-risk MDS
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-185-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.